Differing clinical impact of BRCA1 and BRCA2 mutations in serous ovarian cancer

By Liu Guoyan   Yang Da   Sun Yan   Shmulevich Ilya   Xue Fengxia   Sood Anil K   Zhang Wei  

Pharmacogenomics, Vol. 13, Iss. 13, 2012-10 ,pp. : 1523-1535

Future Medicine

Access to resources Recommend Favorite

Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian

By Mersch Jacqueline   Jackson Michelle A.   Park Minjeong   Nebgen Denise   Peterson Susan K.   Singletary Claire   Arun Banu K.   Litton Jennifer K.  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 269-75

Blackwell Publishing

Access to resources Recommend Favorite

Bevacizumab Combination Therapy: For the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

By Dhillon Sohita  

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 917-930

Adis International

Access to resources Recommend Favorite

Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico

By Villarreal-Garza Cynthia   Alvarez-Gómez Rosa María   Pérez-Plasencia Carlos   Herrera Luis A.   Herzog Josef   Castillo Danielle   Mohar Alejandro   Castro Clementina   Gallardo Lenny N.   Gallardo Dolores   Santibáñez Miguel   Blazer Kathleen R.   Weitzel Jeffrey N.  

Cancer, Vol. 121, Iss. 3, 2015-02 ,pp. : 372-378

Blackwell Publishing

Access to resources Recommend Favorite

BRCA1 and BRCA2 germline mutations are frequently demonstrated in both high-risk pancreatic cancer screening and pancreatic cancer cohorts

By Lucas Aimee L.   Frado Laura E.   Hwang Caroline   Kumar Sheila   Khanna Lauren G.   Levinson Elana J.   Chabot John A.   Chung Wendy K.   Frucht Harold  

Cancer, Vol. 120, Iss. 13, 2014-07 ,pp. : 1960-1967

Blackwell Publishing

Access to resources Recommend Favorite